Adapalene gel vs. Biafine for acute radiation dermatitis in adults receiving radiotherapy
Official title: A Single-Center, Open-Label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Adapalene Gel in Patients Receiving Radiotherapy Who Develop Acute Radiation Dermatitis
Run by Yunnan Cancer Hospital · NCT07886320 · Data updated 2026-11-12
A gel containing adapalene is being tested to see if it helps with skin injury from radiation compared with Biafine in adults undergoing radiotherapy.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Sex | Women only |
| Enrollment | 50 (estimated) |
| Sponsor | Yunnan Cancer Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Kunming, Yunnan) |
| Status | Recruiting |
| Started | March 1, 2026 |
| Main results expected | November 30, 2026 |
| Study ends | November 30, 2026 |
| Registry record updated | October 26, 2026 |
| Trial ID | NCT07886320 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–75 with breast cancer or head and neck cancer planning involved-field radiotherapy and who have grade I–III radiation dermatitis.
✕Probably not a fit
Patients without radiation dermatitis progression or those not meeting inclusion criteria may not benefit from this topical approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This early-phase, randomized trial compares topical adapalene gel 0.1% to Biafine for treating acute radiation-induced skin injury in adults with breast cancer or head and neck cancer. Participants will apply the assigned treatment daily during radiotherapy and visit the clinic every five days for skin assessments, imaging, labs, and symptom reporting. Outcomes include skin reaction severity, safety signals, inflammatory markers, symptoms, and quality of life at multiple time points during treatment and follow-up. The study aims to establish timing, dose, safety monitoring, and potential clinical benefit of topical retinoids for radiation dermatitis across different injury grades.
Why it matters
Potential benefit: If successful, patients may experience reduced skin damage and improved comfort during radiotherapy.
How similar studies have gone: Previous research on topical retinoids for radiation dermatitis is limited; this study explores a novel application in this setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Informed consent: All subjects must voluntarily participate in the study and sign a written informed consent form that meets the requirements of the ethics committee. * Male or female, aged between 18 and 75 years. * Histologically or cytologically confirmed breast cancer or squamous cell carcinoma of the head and neck. * Planned to receive involved-field radiotherapy (post-breast cancer surgery whole breast/chest wall ± regional lymph node irradiation). Exclusion Criteria: * Patients unable to cooperate with the study: cognitive impairment, severe mental illness, communication disorders, or other reasons (such as extreme anxiety, uncontrollable pain) that prevent understanding and active cooperation with the research process and postoperative care. * Any previous or current illnesses, treatments, or laboratory abnormalities that may confound the study results, affect the subjects' full participation in the study, or involve participation that may not be in the subjects' best interests.
Where it's running
-
Yunnan Cancer Hospital
Kunming, Yunnan, China Recruiting
Study contacts
- Study coordinator: 浩瑜 李, graduate student
- Email: 2489181721@qq.com
- Phone: +86 18987725475
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Mepitel Film for Preventing Radiation Dermatitis in Breast Cancer Patients in Singapore
This observational study tests whether Mepitel Film can help prevent radiation dermatitis in breast cancer patients getting whole breast or chest wall radiotherapy in Singapore.
-
Prussian blue nanozyme with near-infrared heat to heal severe radiation dermatitis after head and neck radiotherapy
This will try a Prussian blue–based nanozyme together with near-infrared heat therapy to help heal Grade III radiation dermatitis in people receiving high‑dose radiotherapy for head and neck cancer.
-
Amino acid–derived antioxidant lipids to prevent and treat radiation skin damage in head and neck cancer
This trial will try a new amino acid–based lipid treatment that soaks up harmful reactive oxygen species to prevent or lessen radiation dermatitis in people receiving high‑dose radiotherapy for head and neck cancer.
-
Skin-repair cream to prevent radiation dermatitis after breast cancer surgery
This phase 3 trial tests whether a natural weak-acid skin repair cream can prevent acute radiation dermatitis in adults who had mastectomy and are receiving adjuvant radiotherapy for breast cancer.
-
ROS-scavenging nanoenzyme prevention for radiation dermatitis in head and neck cancer
This trial will try to see if giving novel ROS-scavenging nanoenzymes can prevent radiation-related skin damage in people receiving high-dose radiotherapy for head and neck cancer.
-
Comparing Betamethasone and Moisturizer for Skin Care in Breast Cancer Patients
This study is testing whether a skin cream called betamethasone can help prevent skin problems from radiation therapy in large-breasted breast cancer patients compared to using just a moisturizer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.